人凝血因子IX突变型研究现状

血友病B是一种性连锁隐性遗传病,其发病机制是位于X染色体上的人凝血因子IX(hFIX)基因发生了突变,导致血浆中hFIX含量或活性大幅下降,从而使得内源性凝血途径受到阻碍,无法进行正常的凝血。文章综述了hFIX基因及其编码蛋白质的结构和功能,并分类详细论述了血友病B中发现的几种主要突变类型。其中包括奠基者效应造成的突变、调控区的突变、编码区的突变、内含子剪切位点的突变及另外两种较为特殊的突变,同时介绍了这些突变所造成的生物学效应。最后还简要介绍了一种能提高hFIX蛋白凝血活性的突变类型(第338位Arg→Ala),并对其应用作了展望。     

人凝血因子Ⅸ突变型研究现状

血友病B是一种性连锁隐性遗传病,其发病机制是位于X染色体上的人凝血因子Ⅸ(hFIX)基因发生了突变,导致血浆中hFIX含量或活性大幅下降,从而使得内源性凝血途径受到阻碍,无法进行正常的凝血.文章综述了hFIX基因及其编码蛋白质的结构和功能,并分类详细论述了血友病B中发现的几种主要突变类型.其中包括奠基者效应造成的突变、调控区的突变、编码区的突变、内含子剪切位点的突变及另外两种较为特殊的突变,同时介绍了这些突变所造成的生物学效应.最后还简要介绍了一种能提高hFIX蛋白凝血活性的突变类型(第338位Arg→Ala),并对其应用作了展望.     

利用烟草表达人凝血IX因子 (hFIX)的研究

血友病B是凝血IX因子（hFIX）缺乏所导致的一种出血性疾病,通过输血和hFIX浓缩剂进行治疗疗效显著,但存在治疗费用高和安全隐患,因而获得安全、廉价的人凝血IX因子对血友病B治疗具有重要意义。植物系统表达外源蛋白在生产成本和安全性方面具有优势。为此,本研究构建含人凝血IX因子基因（hFIX,2.8kb）植物双元表达载体p35s-2300：：gus：：noster,用农杆菌介导法转化烟草 "百日红",通过PCR和Southern blot分析证实获得4株独立转基因植株, hFIX在转基因烟草基因组中的拷贝数为1-4个;RT-PCR和ELISA检测结果表明,hFIX在转录和翻译水平已成功表达,hFIX在转基因烟草叶片中的表达量为2.5~8.8ng/g·FW,并具有免疫活性。本研究为利用植物系统表达hFIX的后续研究作了必要准备,也为利用植物系统表达其他药用蛋白研究提供了一些理论和实验参考。     

利用烟草表达人凝血Ⅸ因子(hFIX)的研究

血友病B是凝血Ⅸ因子(hFIX)缺乏所导致的一种出血性疾病,通过输血和hFIX浓缩剂进行治疗疗效显著,但存在治疗费用高和安全隐患,因而获得安全、廉价的人凝血Ⅸ因子对血友病B治疗具有重要意义.植物系统表达外源蛋白在生产成本和安全性方面具有优势.为此,构建含人凝血Ⅸ因子基因(hFIX,2.8kb)植物双元表达载体p35s-2300∷gus∷noster,用农杆菌介导法转化烟草"百日红",通过PCR和Southern blot分析证实获得4株独立转基因植株,hFIX在转基因烟草基因组中的拷贝数为1～4个;RT-PCR和ELISA检测结果表明,hFIX在转录和翻译水平已成功表达,hFIX在转基因烟草叶片中的表达量为2.5～8.8ng/g·FW,并具有免疫活性.为利用植物系统表达hFIX的后续研究作了必要准备,也为利用植物系统表达其他药用蛋白研究提供了一些理论和实验参考.     

利用烟草表达人凝血IX因子(hFIX)的研究

血友病B是凝血IX因子(hFIX)缺乏所导致的一种出血性疾病,通过输血和hFIX浓缩剂进行治疗疗效显著,但存在治疗费用高和安全隐患,因而获得安全、廉价的人凝血IX因子对血友病B治疗具有重要意义。植物系统表达外源蛋白在生产成本和安全性方面具有优势。为此,构建含人凝血IX因子基因(hFIX,2.8kb)植物双元表达载体p35s2300∷gus∷noster,用农杆菌介导法转化烟草“百日红”,通过PCR和Southernblot分析证实获得4株独立转基因植株,hFIX在转基因烟草基因组中的拷贝数为1～4个;RTPCR和ELISA检测结果表明,hFIX在转录和翻译水平已成功表达,hFIX在转基因烟草叶片中的表达量为2.5～8.8ng/g·FW,并具有免疫活性。为利用植物系统表达hFIX的后续研究作了必要准备,也为利用植物系统表达其他药用蛋白研究提供了一些理论和实验参考。     

人羊水祖细胞的分离和基因修饰

探讨从孕中期羊水中分离出人羊水祖细胞的有效方法和FIX基因修饰后的效果,为血友病B的产前治疗提供可行的基础。从镜下分离出呈致密克隆生长的梭形细胞集落,经培养传代后,通过第3代慢病毒载体将hFIX导入该细胞,经酶联免疫反应(ELISA)等方法检测hFIX的表达并检测凝血活性。用这种方法得到的羊水祖细胞呈成纤维细胞样,倍增时间为39.05 h,该细胞在不仅在蛋白水平表达干细胞表面分子SSEA4,TRA1-60,在基因水平还可检测到NANOG,OCT4,SOX2mRNA的表达。羊水祖细胞导入hFIX cDNA后,能合成并分泌hFIX蛋白,传代后48 h在上清液中的浓度为20.37%±2.77%,凝血活性16.42%±1.78%。上清液中的浓度在第4天达到平台期,为50.35%±5.42%,凝血活性可达45.34%±4.67%。ELISA检测显示转染后的羊水细胞表达的hFIX蛋白的水平呈现基本稳定趋势,波动幅度较小;同时检测FIX凝血活性也与蛋白浓度呈正相关。从羊水中可以分离得到具有多能性祖细胞,转染了hFIX的羊水祖细胞在体外能持续合成有凝血功能的hFIX蛋白,为血友病B产前治疗的新方法提供了实验依据。     

人凝血IX因子基因乳腺组织特异性表达载体的构建及其在奶山羊乳腺中的分泌性表达

血友病B(Hernophilia B)是由于人凝血IX因子(hFIX)缺乏所致的一种严重出血性疾病。常规治疗方法是通过输血或输入人浓缩凝血IX园子来实现的,因此患者很容易被肝炎病毒甚至爱滋病毒感染。近年来,人们期望通过转基因动物乳腺表达并从乳汁中分离生产hFIX蛋白,以解除血友病患者的痛苦。以转基因动物的乳腺组织即乳腺生物反应器生产外源蛋白具有原核生物,酵母以及离俸真核细胞生产系统所不具备的优点：生产的外源蛋白经过体内加工和修饰,特别是真核蛋白的转译后加工(如糖基化和羧基化)．其生化特性、生物学活性与天然蛋白完全相同^[1];另外从乳汁中生产外源蛋白不需要复杂的工厂设备。因此开展人凝血IX因子乳腺生物反应器的研究具有重要的经济意义和临床应用价值。转基因动物乳腺生物反应器的关键在于外源基因乳腺组织特异性表达载体的构建。我们利用小鼠MAR元件(Matrix attachment regions)．牛的β-casein基因调控顺序,hFIX mini-gene和hFIX cDNA分别建成两种乳腺组织特异性表达载体pMCIXm和pMCIX,经SA脂质体包埋载体DNA后直接转染奶山 羊乳腺小叶,hFIX蛋白在奶山革乳汁中获得瞬间分泌性表达,最高表达量为13.7ng/ml乳汁。其中含hFIX mini-gene的表达载体在奶山羊乳汁中的表达量高于含hFIX cDNA的表达载体．表明hFIX的in-tronl能够提高该基因在活体奶山羊乳腺中的表达。A7单抗和柠檬酸钡吸附检测表明乳汁中的hFIX 蛋白羧基化和活性比率都在90％以上。以上结果肯定了载体构建的正确性．不但为研制hFIX蛋白乳腺生物反应器提供了有效的表达载体,同时也表明利用阳离子SA脂质体包埋质粒DNA直接转染活体物乳腺可以作为验证乳腺表达载体构建正确性的快速检测手段。     

肿瘤发生与相关基因突变的关联

肿瘤的发生常与其相关基因的突变有关,这些突变会引起编码基因的蛋白质的结构或数量的改变,从而导致其相关基因功能的丧失。突变在基因上发生的位置及类型的不同也会对基因的表达造成不同的影响。本文介绍了存在于肿瘤相关基因编码区及非编码区的突变与肿瘤发生发展的相互关系。本文还就肿瘤相关基因的突变类型阐述肿瘤的靶向治疗,提供了癌症治疗及预防的新思路。     

山羊β-酪蛋白基因启动子指导的转基因小鼠乳汁高效表达人凝血因子IX

为探讨应用转基因动物乳腺生物反应器高效表达人凝血因子IX(human clotting factor IX,hFIX)的可行性,构建了包括山羊β-酪蛋白基因启动子和外显子l、内含子1、外显子2共约6.7kb片段以及hFIX全长cDNA序列和部分经改造的内含子l的乳腺表达载体,通过转基因技术获得12个原代转基因小鼠(9♀,3♂),整合率为11.2%.经EuSA和western b1ot鉴定8只转基因母鼠乳汁中有hFIX的表达并拥有很高的凝血活性,其中一只的表达量高达52.9mg/L,其凝血活性亦高达279.2%.FISH实验表明不同的转基因小鼠外源基因整合于小鼠的不同染色体上.结果证明所构建的山羊β-酪蛋白基因启动子乳腺表达载体能有效指导hFIX基因在小鼠乳腺中高效表达,并能保持hFIX的生物活性.     

枯草芽胞杆菌BSD-2中ybfB基因敲除及生物信息学分析

在前期突变体库研究中发现,ybf B缺失的枯草芽胞杆菌Bacillus subtilis BSD-2丧失了其抑真菌活性。本研究通过敲除并恢复BSD-2中ybf B基因,进一步确认其缺失对菌株生物活性的影响,并利用生物信息学手段对其基因序列和编码蛋白质序列进行了预测分析。本研究成功敲除BSD-2菌株的ybf B基因,构建突变株B-Y-k,并成功构建其回复突变株B-Y,平板对峙实验结果显示突变其ybf B基因该菌株失去其抗真菌活性,回复突变株抗真菌活性恢复,表明该基因与其抗真菌相关。生物信息学分析显示该基因全长1 251 bp,编码416个氨基酸,具有12个跨膜螺旋区,为疏水性蛋白,推测该蛋白为疏水性跨膜转运蛋白,可能参与活性物质的转运。     

High expression of human clotting factor IX cDNA in myoblasts C2C12 cells and C3H mice

Mouse myoblast C2C12 cell was used as target cell for gene transfer study of human clotting factor IX (hFIX) cDNA. In addition to the previously constructed retroviral vectors XLIX, LNCIX and GINaCIX, GlNaMCIX with hFIX driven by muscle creatine kinase (MCK) enhancer and human cytomegalovirus (CMV) was constructed, based on the retroviral vector GINa. These four retroviral vectors were used to transduce mouse my-oblasts C2C12. With ELISA assays, it has been found that the expression levels of human clotting factor IX detected in those transduced C2C12 cells are GlNaMCIX>GlNaCIX> LNCIX>XLIX. Mixed colonal cells transduced with GlNaMCIX expressed hFIX protein at the level of 640 ng/106 cell every 24 h. The modified C2C12 cells transduced with GlNaMCIX were implanted into skeletal muscle of the hindlegs of C3H mice; a stable expression of hFIX was detected and lasted for 35 d, with a maximum level of 206 ng/mL plasma. The regulation of hFIX cDNA expression in myoblasts was discussed and it was strongly sug     

Skeletal muscle-specific expression of human blood coagulation factor IX rescues factor IX deficiency mouse by AAV-mediated gene transfer

The efficacy of recombinant adeno-associated virus (AAV) vector to deliver and express human blood clotting factor IX (hFIX) gene in skeletal muscle of coagulation factor IX deficiency mouse strain (FactorIX-knockout) is evaluated. The muscle creatine kinase enhancer (MCK) and β-actin promoter (βA) were used to drive the hFIX minigene (hFIXml), which was flanked by AAV inverted terminal repeats (ITRs). Following intramuscular injection of high titer (2.5 × 10¹¹ vector genomes/mL) of rAAV, increased hFIX expression (256 ng/mL of plasma) was achieved. The time course of hFIX expression demonstrated that the expression level gradually increased over a period of two weeks before anti-hFIX antibodies developed in mouse circulating plasma. Those results provided a promising evidence that rAAV-mediated gene transfer and skeletal muscle-specific expression of hFIX is a feasible strategy for treating patients for hemophilia B.     

Transgenic Mice Can Express Mutant Human Coagulation Factor IX with Higher Level of Clotting Activity

To improve the available values of transgenic animals, we produced a mutant human coagulation factor IX minigene (including cDNA and intron I) with arginine at 338 changed to alanine (R338A-hFIX) by using a direct mutation technique. The R338A-hFIX minigene was then cloned into a plasmid carrying the goat β-casein promoter to get a mammary gland-specific expression vector. The clotting activity in the supernatant of the transfected HC-11 cells increased to approximately three times more than that of wild-type hFIX. Nine transgenic mice (three females and six males) were produced, and the copy number of the foreign gene was very different, ranging from 1 to 43 in different lines. ELISA, Western blot, and clotting assay experiments showed that the transgenic mice could express R338A-hFIX, showing higher average levels of clotting activity than wild-type hFIX in the milk (103.76% vs. 49.95%). The highest concentration and clotting activity of hFIX reached 26 μg/mL and 1287% in one founder (F₀-7), which was over 10 times higher than that in human plasma. Furthermore, RT-PCR, APTT assay, and histological analysis indicated that hFIX was expressed specifically in the mammary gland without affecting the intrinsic coagulation pathway and physiologic performance of the local tissue.     

Expression and regulation of hFIX minigene and cDNA driven by β-casein gene in mouse mammary gland

Mammary gland specific expression vectors for human clotting factor IX (hFIX) and LacZ reporter gene driven by bovine β-casein gene were constructed. Vectors were packaged by stearylamine (SA) liposome and were transferred to lactating mice via tail vein. Both hFIX and Lac2 gene could be expressed in the mammary gland of the treated mice. The highest production of hFIX protein was 80.28 ng per mL milk, and more than 85% of hFIX protein appeared to be γ-carboxylation and biologically active. The results suggested that the 2.0 kb sequence of β-casein gene including promoter, exon 1 was effective to drive hFIX gene expression in mammary gland and intron 1 of β-casein gene had an effect on the tissue specific expression. The expression level in mouse milk injected with hFIX minigene vector containing hFIX endogenous intron 1 was increased by above 3 times of that injected with hFIX cDNA vector.     

Limitation in use of heterologous reporter genes for gene promoter analysis. Silencer activity associated with the cloramphenicol acetyltransferase reporter gene

Various heterologous reporter genes have been widely used for the functional characterization of gene promoters. Many such studies often found weak to very strong silencer activities to be associated with specific parts of the basal promoter or further upstream regions. In this study, we carried out a systematic study on human blood coagulation factor IX (hFIX) and anti-coagulant protein C (hPC) genes, previously shown to have silencer activities associated with their 5'-flanking regions containing promoter sequences. With newly constructed chloramphenicol acetyltransferase (CAT) reporter vectors carrying hFIX or hPC gene promoter sequences, we confirmed the strong silencer activities associated with the regions nt -1895 through nt -416 of the hFIX gene or with the region nt -802 through nt -82 of the hPC gene. However, no such silencer activities associated with the specific regions were found when autologous hFIX cDNA, hFIX minigenes, or hPC minigenes were used as reporters in the expression vector system. Relative levels of CAT, hFIX, and hPC proteins produced in the transient assays correlated well with their mRNA levels. Human FIX minigene constructs containing a simian virus 40 (SV40) 3'-untranslated region (UTR) taken from the CAT reporter gene showed no silencer activity, indicating that SV40 3'-UTR sequence of the CAT reporter gene does not contribute to the silencer activity. Expression vectors constructed with the beta-galactosidase gene under the control of hFIX gene promoter sequences also showed no silencer activity associated with the region nt -1895 through nt -416. These findings indicate that silencer activities associated with specific regions of promoter sequences as analyzed with CAT reporter genes may represent artifacts specific to the CAT reporter genes. Our findings strongly suggest a need for re-examination of promoter characterizations of many eukaryotic genes, which have been studied to date with CAT reporter genes.     

Injecting skin fibroblasts into muscles to express human clotting factor IX cDNA

Ｉｔｉｓｅａｓｙｔｏｄｅｒｉｖｅｐｒｉｍａｒｙｍｙｏｂｌａｓｔｓｆｒｏｍｈｕｍａｎｂｉｏｐｓｙ.Ｔｈｅｔｒａｎｓｆｏｒｍｅｄｍｙｏｂｌａｓｔｓｃｏｕｌｄｅｘｐｒｅｓｓｆｏｒｅｉｇｎｇｅｎｅａｔｈｉｇｈｌｅｖｅｌ.Ｂｕｔｌｅｓｓｍｙｏｂｌａｓｔｓｅｘｉｓｔｉｎａｄｕｌｔｓ[1],ａｎｄａｒｅｌｉａｂｌｅｔｏｄｉｆｆｅｒｅｎｔｉａｔｅａｎｄｆａｉｌｔｏｄｉｖｉｄｅ,ｌｅａｄｉｎｇｔｏｌｏｗｅｆｆｉｃｉｅｎｃｙｏｆｔｒａｎｓｆｅｃｔｉｏｎａｎｄａｍｐｌｉｆｉｃａｔｉｏｎｉｎｖｉｔｒｏ,ａｎｄｓｕｂｓｅｑｕｅｎ…     

Skeletal muscle-specific expression of human blood coagulation factor Ⅸ rescues factor Ⅸ deficiency mouse by AAV-mediated gene transfer

The efficacy of recombinant adeno-associated virus (AAV) vector to deliver and express human blood clotting factor DC (hFIX) gene in skeletal muscle of coagulation factor IX deficiency mouse strain (FactorIX-knockout) is e-valuated. The muscle creatine kinase enhancer (MCK) and βactin promoter ((3A) were used to drive the hFIX minigene (hFIXml), which was flanked by AAV inverted terminal repeats (ITRs). Following intramuscular injection of high liter (2.5 x 1011 vector genomes/mL) of AAV, increased hFIX expression (256 ng/mL of plasma) was achieved. The time course of hFIX expression demonstrated that the expression level gradually increased over a period of two weeks before anti-hFIX antibodies developed in mouse circulating plasma. Those results provided a promising evidence that rAAV-me-diated gene transfer and skeletal muscle-specific expression of hFIX is a feasible strategy for treating patients for hemophilia B.     

Expression and regulation of hFIX minigene and cDNA driven by β-casein gene in mouse mammary gland

Mammary gland specific expression vectors for human clotting factor IX (hFIX) and LacZ reporter gene driven by bovine β-casein gene were constructed. Vectors were packaged by stearylamine (SA) liposome and were transferred to lactating mice via tail vein. Both hFIX and Lac2 gene could be expressed in the mammary gland of the treated mice. The highest production of hFIX protein was 80.28 ng per mL milk, and more than 85% of hFIX protein appeared to be γ-carboxylation and biologically active. The results suggested that the 2.0 kb sequence of β-casein gene including promoter, exon 1 was effective to drive hFIX gene expression in mammary gland and intron 1 of β-casein gene had an effect on the tissue specific expression. The expression level in mouse milk injected with hFIX minigene vector containing hFIX endogenous intron 1 was increased by above 3 times of that injected with hFIX cDNA vector. Project supported by the State High Technology Development Program and Shanghai Science and Technology Commission.     

Encapsulated human primary myoblasts deliver functional hFIX in hemophilic mice

BACKGROUND: Hemophilia B is a bleeding disorder caused by defective factor IX (FIX), currently treated by regular infusions of plasma-derived or recombinant FIX. We propose a gene therapy strategy based on the implantation of cells secreting FIX enclosed in alginate microcapsules as a highly desirable alternative treatment. We have reported sustained delivery of human factor IX (hFIX) in immunocompetent mice implanted with encapsulated primary mouse myoblasts engineered to secrete hFIX. As a step towards the treatment of human patients, in this study we report the implantation of encapsulated human primary myoblasts secreting hFIX in hemophilia B mice. METHODS: Human primary myoblasts were transfected with plasmids pKL4M-hFIX, pLNM-betaIXL, pMFG-hFIX, and transduced with retrovirus MFG-hFIX. Two human primary myoblast clones secreting approximately 1 microg hFIX/10(6) cells/day were enclosed in biocompatible alginate microcapsules and implanted intraperitoneally into SCID and hemophilic mice. RESULTS: Circulating hFIX (peak of approximately 120 ng/ml) was detected in hemophilia B mice on day 1 after implantation. Human FIX delivery was transient, however, becoming undetectable on day 14. Concurrently, anti-hFIX antibodies were detected. At the same time, activated partial thromboplastin time (APTT) was reduced from 94 s before treatment to 78-80 s. Tail bleeding time decreased from 15 min to 1.5-7 min after treatment, some mice being normalised. These findings indicate that the delivered hFIX is biologically active. Similarly treated NOD/SCID mice had circulating hFIX levels of 170 ng/ml on day 1 that remained detectable for 1 month, albeit at low levels. Cell viability of microcapsules retrieved on day 60 was below 5%. CONCLUSIONS: Our findings indicate that encapsulated human primary myoblasts secrete functional hFIX. Furthermore, implantation of encapsulated human primary myoblasts can partially correct the phenotype of hemophilia B mice, supporting the feasibility of this gene therapy approach for hemophilia B. However, the long-term viability of the encapsulated human myoblasts must first be improved.